A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
Haematology Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies April 26, 2019 An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…